Argenx Se (ARGX) Cash & Current Investments (2015 - 2026)
Argenx Se (ARGX) posted quarterly Cash & Current Investments of $5.2 billion for Q2 2026, down 99.55% year-on-year from $1156.3 billion in Q2 2025, and up 16.76% on a QoQ basis from $4.4 billion in Q4 2025.
Argenx Se (ARGX) Cash & Current Investments (2015 - 2026) Analysis & Trends
Argenx Se (ARGX) has reported Cash & Current Investments for 12 consecutive years, with $5.2 billion the latest figure, recorded in Q2 2026.
- Quarterly Cash & Current Investments fell 99.55% year-over-year to $5.2 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $5.2 billion (down 99.55% YoY) and the FY2025 annual result came in at $5.9 billion, up 960.14% from the prior year.
- Cash & Current Investments rose to $5.2 billion in Q2 2026 per ARGX's latest filing, from $4.4 billion in the prior quarter.
- Over the last five years, Cash & Current Investments for ARGX reached as high as $1156.3 billion in Q2 2025 and fell as low as -$1107.0 billion in Q2 2024.
- A 5-year average of $8.0 billion and a median of $3.2 billion in 2023 frame the typical range for Cash & Current Investments.
- Annual changes were most pronounced in 2024 — Cash & Current Investments tumbled 55532.62% — and 2025, when it surged 204.46%.
- Year by year, Cash & Current Investments stood at $2.2 billion in 2022, then surged by 45.03% to $3.2 billion in 2023, then advanced by 6.26% to $3.4 billion in 2024, then jumped by 31.4% to $4.4 billion in 2025, then advanced by 16.76% to $5.2 billion in 2026.
- According to Business Quant data, Cash & Current Investments over the past three periods registered $5.2 billion, $4.4 billion, and $1156.3 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 283.54 Mn |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - | - |
| 4 | BeOne Medicines | 470.64 Bn | 465.84 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 122.91 Bn | 115.67 Bn | 2.59 Bn | 7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn | 8.75 Bn |
| 7 | Belite Bio | 62.77 Bn | 62.77 Bn | - | - |
| 8 | Argenx Se | 56.21 Bn | 51.02 Bn | 1.41 Bn | 5.18 Bn |
| 9 | Revolution Medicines | 37.60 Bn | 37.60 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 37.34 Bn | 34.33 Bn | 959.66 Mn | 3.01 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.18 Bn |
| Dec 31, 2025 | 4.44 Bn |
| Jun 30, 2025 | 1,156.35 Bn |
| Dec 31, 2024 | 3.38 Bn |
| Jun 30, 2024 | -1,106.97 Bn |
| Dec 31, 2023 | 3.18 Bn |
| Jun 30, 2023 | 2.00 Bn |
| Dec 31, 2022 | 2.19 Bn |
| Jun 30, 2022 | 2.60 Bn |
| Dec 31, 2021 | 2.34 Bn |
| Jun 30, 2021 | 2.73 Bn |
| Dec 31, 2020 | 1.85 Bn |
| Jun 30, 2020 | 2.20 Bn |
| Dec 31, 2019 | 1.52 Bn |
| Jun 30, 2019 | 1.07 Bn |
| Dec 31, 2018 | 642.45 Mn |
| Jun 30, 2018 | 489.03 Mn |
| Dec 31, 2017 | 519.23 Mn |
| Jun 30, 2017 | 250.29 Mn |
| Dec 31, 2016 | 139.60 Mn |